2023年美国国立综合癌症网络（NCCN）中枢神经系统肿瘤指南更新 - Suppr

NCCN CNS tumor guidelines update for 2023.

作者信息

Nabors Burt, Portnow Jana, Hattangadi-Gluth Jona, Horbinski Craig

机构信息

Department of Neurology, Division of Neuro-oncology; Departments of Neurology and Neurosurgery, O'Neal Comprehensive Cancer Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.

Department of Medical Oncology and Research Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California.

出版信息

Neuro Oncol. 2023 Dec 8;25(12):2114-2116. doi: 10.1093/neuonc/noad169.

DOI:10.1093/neuonc/noad169

PMID:37706665

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10708932/

Abstract

摘要

相似文献

NCCN CNS tumor guidelines update for 2023.

Neuro Oncol. 2023 Dec 8;25(12):2114-2116. doi: 10.1093/neuonc/noad169.

Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 2020 Nov 2;18(11):1537-1570. doi: 10.6004/jnccn.2020.0052.

Central Nervous System Cancers, Version 1.2015.

J Natl Compr Canc Netw. 2015 Oct;13(10):1191-202. doi: 10.6004/jnccn.2015.0148.

NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022.

J Natl Compr Canc Netw. 2023 Jan;21(1):12-20. doi: 10.6004/jnccn.2023.0002.

Guidelines in the management of CNS tumors.

J Neurooncol. 2021 Feb;151(3):345-359. doi: 10.1007/s11060-020-03530-8. Epub 2021 Feb 21.

NCCN Guidelines(R) Updates.

J Natl Compr Canc Netw. 2013 Sep 1;11(9):xxxii-xxxvi.

Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 2022 Dec;20(12):1339-1362. doi: 10.6004/jnccn.2022.0062.

An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC).

BMC Cancer. 2022 Jan 16;22(1):70. doi: 10.1186/s12885-022-09179-y.

Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:148-157. doi: 10.1200/EDBK_200989.

[The First Step in a Long-Run-Celebrating the announcement of "Guideline for the management of CNS gliomas in China"].

Zhonghua Yi Xue Za Zhi. 2013 Aug 20;93(31):2417.

引用本文的文献

Dexamethasone in brain tumor patients: a real-world pharmacovigilance audit.

Front Neurol. 2025 Aug 20;16:1632231. doi: 10.3389/fneur.2025.1632231. eCollection 2025.

Impact of Irradiation on Post-Surgical Residuals of WHO Grade I Meningioma.

J Clin Med. 2025 Aug 18;14(16):5829. doi: 10.3390/jcm14165829.

Clinical Predictors and Recurrence Characteristics Following Radiotherapy for Primary Central Nervous System Lymphoma: A Retrospective Cohort Study.

Cancers (Basel). 2025 Jun 27;17(13):2176. doi: 10.3390/cancers17132176.

Editorial: Clinical therapy of brain tumors.

Front Neurol. 2025 May 23;16:1610463. doi: 10.3389/fneur.2025.1610463. eCollection 2025.

Brain Metastases from Genito-Urinary Cancers in the Canton of Geneva (Switzerland): Study of Incidence, Management and Outcomes.

Cancers (Basel). 2024 Oct 10;16(20):3437. doi: 10.3390/cancers16203437.

Current challenges in the treatment of gliomas: The molecular era.

World J Clin Oncol. 2024 Aug 24;15(8):982-986. doi: 10.5306/wjco.v15.i8.982.

Stereotactic body radiotherapy for spinal oligometastases: a survey on patterns of practice on behalf of the Italian Association of Clinical Oncology and Radiotherapy (AIRO).

Clin Exp Metastasis. 2024 Oct;41(5):679-685. doi: 10.1007/s10585-024-10304-3. Epub 2024 Aug 1.

MGMT promoter methylation is a strong prognostic factor for survival after progression in high-grade gliomas.

Chin Neurosurg J. 2024 Jul 24;10(1):24. doi: 10.1186/s41016-024-00375-2.

Treatment of IDH-mutant glioma in the INDIGO era.

NPJ Precis Oncol. 2024 Jul 19;8(1):149. doi: 10.1038/s41698-024-00646-2.

State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond.

Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e431450. doi: 10.1200/EDBK_431450.

本文引用的文献

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.

Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.

Lancet Oncol. 2021 Jun;22(6):813-823. doi: 10.1016/S1470-2045(21)00090-5. Epub 2021 May 14.

CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.

Neuro Oncol. 2019 Dec 17;21(12):1519-1528. doi: 10.1093/neuonc/noz124.

Letter: When Less is More: Dexamethasone Dosing for Brain Tumors.

Neurosurgery. 2019 Sep 1;85(3):E607-E608. doi: 10.1093/neuros/nyz186.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

NCCN CNS tumor guidelines update for 2023.

作者信息

Nabors Burt, Portnow Jana, Hattangadi-Gluth Jona, Horbinski Craig

机构信息

Department of Medical Oncology and Research Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California.

出版信息

Neuro Oncol. 2023 Dec 8;25(12):2114-2116. doi: 10.1093/neuonc/noad169.

DOI:10.1093/neuonc/noad169

PMID:37706665

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10708932/

Abstract

摘要

相似文献

NCCN CNS tumor guidelines update for 2023.

Neuro Oncol. 2023 Dec 8;25(12):2114-2116. doi: 10.1093/neuonc/noad169.

Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 2020 Nov 2;18(11):1537-1570. doi: 10.6004/jnccn.2020.0052.

Central Nervous System Cancers, Version 1.2015.

J Natl Compr Canc Netw. 2015 Oct;13(10):1191-202. doi: 10.6004/jnccn.2015.0148.

NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022.

J Natl Compr Canc Netw. 2023 Jan;21(1):12-20. doi: 10.6004/jnccn.2023.0002.

Guidelines in the management of CNS tumors.

J Neurooncol. 2021 Feb;151(3):345-359. doi: 10.1007/s11060-020-03530-8. Epub 2021 Feb 21.

NCCN Guidelines(R) Updates.

J Natl Compr Canc Netw. 2013 Sep 1;11(9):xxxii-xxxvi.

Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 2022 Dec;20(12):1339-1362. doi: 10.6004/jnccn.2022.0062.

BMC Cancer. 2022 Jan 16;22(1):70. doi: 10.1186/s12885-022-09179-y.

Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:148-157. doi: 10.1200/EDBK_200989.

[The First Step in a Long-Run-Celebrating the announcement of "Guideline for the management of CNS gliomas in China"].

Zhonghua Yi Xue Za Zhi. 2013 Aug 20;93(31):2417.

引用本文的文献

Dexamethasone in brain tumor patients: a real-world pharmacovigilance audit.

Front Neurol. 2025 Aug 20;16:1632231. doi: 10.3389/fneur.2025.1632231. eCollection 2025.

Impact of Irradiation on Post-Surgical Residuals of WHO Grade I Meningioma.

J Clin Med. 2025 Aug 18;14(16):5829. doi: 10.3390/jcm14165829.

Clinical Predictors and Recurrence Characteristics Following Radiotherapy for Primary Central Nervous System Lymphoma: A Retrospective Cohort Study.

Cancers (Basel). 2025 Jun 27;17(13):2176. doi: 10.3390/cancers17132176.

Editorial: Clinical therapy of brain tumors.

Front Neurol. 2025 May 23;16:1610463. doi: 10.3389/fneur.2025.1610463. eCollection 2025.

Brain Metastases from Genito-Urinary Cancers in the Canton of Geneva (Switzerland): Study of Incidence, Management and Outcomes.

Cancers (Basel). 2024 Oct 10;16(20):3437. doi: 10.3390/cancers16203437.

Current challenges in the treatment of gliomas: The molecular era.

World J Clin Oncol. 2024 Aug 24;15(8):982-986. doi: 10.5306/wjco.v15.i8.982.

Stereotactic body radiotherapy for spinal oligometastases: a survey on patterns of practice on behalf of the Italian Association of Clinical Oncology and Radiotherapy (AIRO).

Clin Exp Metastasis. 2024 Oct;41(5):679-685. doi: 10.1007/s10585-024-10304-3. Epub 2024 Aug 1.

MGMT promoter methylation is a strong prognostic factor for survival after progression in high-grade gliomas.

Chin Neurosurg J. 2024 Jul 24;10(1):24. doi: 10.1186/s41016-024-00375-2.

Treatment of IDH-mutant glioma in the INDIGO era.

NPJ Precis Oncol. 2024 Jul 19;8(1):149. doi: 10.1038/s41698-024-00646-2.

State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond.

Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e431450. doi: 10.1200/EDBK_431450.

本文引用的文献

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.

Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.

Lancet Oncol. 2021 Jun;22(6):813-823. doi: 10.1016/S1470-2045(21)00090-5. Epub 2021 May 14.

CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.

Neuro Oncol. 2019 Dec 17;21(12):1519-1528. doi: 10.1093/neuonc/noz124.

Letter: When Less is More: Dexamethasone Dosing for Brain Tumors.

Neurosurgery. 2019 Sep 1;85(3):E607-E608. doi: 10.1093/neuros/nyz186.

NCCN CNS tumor guidelines update for 2023.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

NCCN CNS tumor guidelines update for 2023.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献